

RESEARCH

Open Access



The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis

Wonkyo Shin¹, Sang-Yoon Park^{1,2}, Sokbom Kang^{1,3,4}, Myong Cheol Lim^{1,4,5,6} and Sang-Soo Seo^{1*} 

Abstract

Purpose: We investigated the effect of ovary preserving surgery in early International Federation of Obstetrics and Gynecology (FIGO) stage endometrial cancer patients.

Methods: Medical records were retrospectively reviewed for 539 patients who were diagnosed with early stage endometrial cancer between Jan 2006 and Dec 2017. Patients were categorized into ovary preservation and ovary removal groups. Demographics, recurrence free survival (RFS), and five-year overall survival (OS) rate were compared, and the clinical factors affecting survival were evaluated by univariate and multivariate analysis.

Results: The median follow-up period was 85 months (range, 6–142 months), and the median age was 52.7 years. The mean age was higher in the ovary removal group than in the ovary preservation group (54.4 vs 40.94 years; $P < 0.001$). The ovary preservation group showed an earlier FIGO stage than the ovary removal group ($P = 0.0264$). There was a greater incidence of adjuvant chemotherapy administration in the removal group. There were no statistical differences in other baseline characteristics. When comparing the RFS and OS rates, there were no statistical differences between the preservation and removal groups. (recurrence free rate 98.5% vs 92.7%, $p = 0.4360$, and 5-year survival rate 98.6% vs 93.0%, $p = 0.0892$, respectively). Endometrioid histology ($p = 0.006$) and post-operative adjuvant chemotherapy ($p = 0.0062$) were related to OS, and adjuvant chemotherapy ($p < 0.001$) and radiotherapy ($p = 0.005$) were related to RFS.

Conclusions: Ovary preservation in early stage endometrial cancer is worth considering, as it does not affect survival in early stage endometrial cancer patients.

Keywords: Endometrial cancer, Early stage, Ovary preservation, Menopause

Background

Endometrial cancer has the highest incidence in gynecological cancers in Western countries [1], and the incidence is also increasing in Korea [2]. Conversely, endometrial cancer has a higher rate of early diagnosis than other gynecologic and solid cancers because symptoms such as irregular bleeding or discharge are easily detected

by patients and diagnosis is possible with a simple endometrial curettage or hysteroscopic endometrial biopsy [3].

According to the National Comprehensive Cancer Network (NCCN) guidelines, early stage endometrial cancer is treated with total hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection, with subsequent staging according to the pathologic report. Adjunctive total salpingo-oophorectomy is the standard treatment option, because of the possibility of occult tumor cells in the ovary and the fact that endometrial cancer is advanced by ovarian hormones [4, 5]. The incidence of ovarian tumors in

* Correspondence: ssseomd@ncc.re.kr

¹Center for Gynecologic Cancer, Graduate School of Cancer Science and Policy, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 10408, Republic of Korea

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

patients with endometrial cancer is as 7% [6]. However, surgical menopause caused by removing the ovaries can induce other complications, such as hot flushes, night sweats, vaginal dryness, insomnia, osteoporosis, cardiovascular problem, sexual dysfunction, and cognitive problems that can affect survival and quality of life [7–11]. Exogenous hormone replacement therapy may relieve these menopausal symptoms but can also induce other complications [12, 13].

Meta-analysis [14] and other research [4, 5, 15, 16] on ovarian preservation surgery in young, premenopausal early stage endometrial cancer patients has produced conflicting results. Some studies claim that it is safer to remove the ovaries, although preservation of the ovary generally does not affect patient recurrence or survival. However, in some meta-analyses and reviews, much of the patient data (34.9%) is too old records [4], therefore, there is a risk of inaccurate medical records. Further, studies included incidentally diagnosed cancer patients who were regarded as having benign disease such as leiomyoma or adenomyosis prior to surgery, and only had hysterectomy planned without salpingo-oophorectomy.

In addition, many patients receive adjuvant treatment such as radiotherapy or chemotherapy after ovarian preserving surgery, which can further damage ovarian functions. These cases do not represent true ovarian preservation or help to reduce the complications of surgical menopause.

This retrospective study compares the survival of early International Federation of Obstetrics and Gynecology (FIGO) stage endometrial cancer patients who have the ovaries preserved with those who had the ovaries removed in a real clinical setting.

Methods


Medical records of patients with endometrial cancer who were newly diagnosed by endometrial biopsy and treated at

National Cancer Center in South Korea between January 2006 and December 2017 were reviewed. A total of 1578 endometrial cancer patients visited our outpatient clinics; however, 497 patients visited only once for counseling or a second opinion, and 439 patients had recurrent disease. Another 103 patients were excluded due to advanced cancer status (FIGO stage III or IV), which resulted in 539 patients who had been diagnosed and treated in our center for early (FIGO stage I or II) endometrial cancer (Fig. 1). Clinical factors including age at diagnosis, FIGO stage, FIGO grade, histology of the surgically removed tissues, surgical approach method, radicality of hysterectomy, lymph node dissection, and adjuvant chemotherapy and radiotherapy were collected.

Correlations of variables were assessed using the Fisher's exact or Student *t*-test. Five year overall survival (OS) rates and recurrence free survival (RFS) rates were estimated by Kaplan-Meier analysis. The log-rank test was used to compare survival curves. Cox regression analysis was performed to determine the predictive factors for prognosis with hazard ratios (HRs). *P* values <.05 were considered to be significant. This retrospective study was approved by the institutional review board of our institution (IRB No. NCC2019–0272).

Results

The 539 patients included 469 in the ovarian removal group and 70 in the ovarian preservation group. The ovarian removal group was significantly older than the ovarian preservation group ($P < 0.001$). The FIGO stage was earlier in the ovarian preservation group ($P = 0.0264$). Lymph node dissection was more frequently performed in the ovarian removal group. There was no significant difference between the two groups in terms of surgical approach method, radicality of hysterectomy, or the administration of adjuvant




chemotherapy or radiotherapy (Table 1). The five-year OS and RFS) graphs showed no significant differences between ovarian preservation and removal groups (OS: 98.6% vs.

93.0%, $P = 0.0892$, and RFS: 98.5% vs 92.7%, $P = 0.436$, respectively) (Fig. 2). Adjusted univariate analysis was performed for FIGO stage and patient age. Univariate analysis

Table 1 Patient baseline characteristics

Variables	Total N = 539	Ovary Preserved N = 70	Ovary Removed N = 469	P-value
FIGO Stage				
IA	390 (72.36)	60 (85.71)	330 (70.36)	0.0264
IB	126 (23.38)	8 (11.43)	118 (25.16)	
II	23 (4.27)	2 (2.86)	21 (4.48)	
FIGO grade				
1	293 (54.36)	41 (58.57)	252 (53.73)	0.289
2	141 (26.16)	21 (30)	120 (25.59)	
3	52 (9.65)	5 (7.14)	47 (10.02)	
Etc.	53 (9.83)	3 (4.29)	50 (10.66)	
Histology				
Endometrioid	461 (85.53)	66 (94.29)	395 (84.22)	0.2329
Serous	31 (5.75)	2 (2.86)	29 (6.18)	
CCC	20 (3.71)	1 (1.43)	19 (4.05)	
Mucinous/mixed/Undifferentiated/NE/etc.	27 (5.01)	1 (1.43)	26 (5.54)	
Age (year)				
mean \pm SD	52.68 \pm 10.42	40.94 \pm 9.56	54.43 \pm 9.36	<.0001
< 30	11 (2.04)	8 (11.43)	3 (0.64)	<.0001
31 ~ 35	19 (3.53)	13 (18.57)	6 (1.28)	
36 ~ 40	39 (7.24)	21 (30)	18 (3.84)	
40 ~ 45	51 (9.46)	11 (15.71)	40 (8.53)	
45 >	419 (77.74)	17 (24.29)	402 (85.71)	
Approach				
Laparoscopy	395 (73.28)	60 (85.71)	335 (71.43)	0.0366
Laparotomy	138 (25.6)	10 (14.29)	128 (27.29)	
Etc.	6 (1.11)	0 (0)	6 (1.28)	
Hysterectomy - radicality				
A	489 (90.72)	63 (90)	426 (90.83)	0.7491
B	18 (3.34)	2 (2.86)	16 (3.41)	
C	27 (5.01)	5 (7.14)	22 (4.69)	
Not done	5 (0.93)	0 (0)	5 (1.07)	
PLND				
No	112 (20.78)	23 (32.86)	89 (18.98)	0.0076
Yes	427 (79.22)	47 (67.14)	380 (81.02)	
PALND				
No	251 (46.57)	51 (72.86)	200 (42.64)	<.0001
Yes	288 (53.43)	19 (27.14)	269 (57.36)	
Adjuvant Chemotherapy				
No	455 (84.42)	66 (94.29)	389 (82.94)	0.0147
Yes	84 (15.58)	4 (5.71)	80 (17.06)	
Adjuvant radiotherapy				
No	468 (86.83)	64 (91.43)	404 (86.14)	0.2224
Yes	71 (13.17)	6 (8.57)	65 (13.86)	

CCC clear cell carcinoma, NE neuroendocrine tumor, PLND pelvic lymph node dissection, PALND para-aortic lymph node dissection



demonstrated that FIGO grade, histology, and adjuvant chemotherapy were significantly related to RFS and OS. Adjuvant radiotherapy was related to RFS only. Pelvic lymph node dissection was related to OS only. Neither surgical approach nor radicality of hysterectomy were related to RFS or OS. In multivariate analysis, histology and adjuvant chemotherapy were related to OS, and adjuvant chemotherapy and radiotherapy were related to RFS (Table 2). Compared to endometrioid histology, non-endometrioid histology showed relatively low RFS and OS. Ovarian preservation or removal was not related to RFS or OS.

Discussion

There is no clear consensus on the surgery scale in early stage endometrial cancer patients. Traditionally, total hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection and omentectomy for staging have been performed. According to the NCCN; American Society of Clinical Oncology (ASCO); and European Society for Medical Oncology, European Society of Gynaecological Oncology, and European Society for Radiotherapy & Oncology (ESMO-ESGO-ESTRO) guidelines [3, 17, 18], ovarian preservation can be considered in pre-menopausal early stage endometrial cancer patients. While oophorectomy removes any occult ovarian metastatic tumor and reduces the ovarian cancer risk, surgical menopausal problems can result.

Previous studies have shown that preserving the ovary does not affect survival in patients with early stage endometrial cancer who are not menopausal, compared with those who have had the ovaries removed [4, 5, 14, 15]. Previous studies are compared in Table 3. These retrospective studies were conducted in the United States, China, and Korea, conducted mainly with pre-menopausal women as patient groups. Prospective research has been difficult to perform as recruitment of early stage and premenopausal patients has been challenging. Their results showed that in the case of early stage and low FIGO grade, preservation of the ovary did not affect the prognosis of the patient. Recently, a systemic review summarized previous studies, with more than 10,000 cases, and revealed an increase in OS and no shortening of RFS. In the early stages of premenopausal women, ovarian preservation may be a viable treatment option [19]. The results are similar to ours. However, as previously noted, this research has several limitations, including a large portion of patients with benign disease, the inclusion of patients with adjuvant chemotherapy or radiotherapy after preserving the ovaries [5, 16], or including patients with old records [4]. There are many reports of ovarian function deterioration after radiation or chemotherapy in premenopausal women [20–23]. These cases demonstrate that preserving the ovaries does not result in

Table 2 Univariate and multivariate analysis of prognostic factors

variables	Overall survival				Recurrence Free survival			
	Adjusted model ^a		Multivariable ^b		Adjusted model ^a		Multivariable ^b	
	HR(95% CI)	<i>p</i> -value	HR(95% CI)	<i>p</i> -value	HR(95% CI)	<i>p</i> -value	HR(95% CI)	<i>p</i> -value
	<i>N</i> = 539/EVNET = 31		<i>N</i> = 539/EVNET = 31		<i>N</i> = 539/EVNET = 33		<i>N</i> = 539/EVNET = 33	
Ovary								
preserved	1(ref)				1(ref)			
removed	2.058 (0.266–15.915)	0.4892			0.865 (0.245–3.052)	0.8215		
FIGO grade								
1	1(ref)	0.0103			1(ref)	0.0339		
2	2.305 (0.869–6.116)	0.0935			2.418 (1.052–5.556)	0.0376		
3	4.215 (1.324–13.42)	0.0149			1.176 (0.255–5.416)	0.8355		
etc	5.102 (1.838–14.162)	0.0018			3.807 (1.465–9.894)	0.0061		
Histology								
Endometrioid	1(ref)	0.0013	1(ref)	0.0006	1(ref)	0.0322		
Serous	5.333 (2.206–12.892)	0.0002	5.969 (2.437–14.617)	<.0001	3.548 (1.389–9.062)	0.0081		
CCC	3.381 (0.968–11.806)	0.0562	3.729 (1.064–13.072)	0.0397	3.031 (0.894–10.274)	0.075		
Mucinous/mixed/ Undifferentiated/NE/etc	3.212 (0.921–11.196)	0.067	3.373 (0.963–11.808)	0.0572	1.609 (0.374–6.918)	0.5224		
approach								
Laparoscopy	1(ref)	0.027			1(ref)	0.4568		
Laparotomy	2.298 (1.058–4.992)	0.0355			1.604 (0.765–3.36)	0.2106		
etc	7.88 (0.974–63.726)	0.0529			–	0.9883		
Hysterectomy - radicality								
A	1(ref)	0.2591			1(ref)	0.9624		
B	–	0.9901			0.598 (0.073–4.913)	0.6322		
C	0.443 (0.091–2.159)	0.3139			0.776 (0.162–3.704)	0.7503		
Not done	6.183 (0.769–49.733)	0.0868			–	0.9887		
PLND								
No	1(ref)				1(ref)			
Yes	0.371 (0.162–0.852)	0.0194			0.549 (0.24–1.256)	0.1556		
PALND								
No	1(ref)				1(ref)			
Yes	0.848 (0.407–1.766)	0.6593			1.008 (0.491–2.068)	0.9826		
Adjuvant chemotherapy								
No	1(ref)		1(ref)		1(ref)		1(ref)	
Yes	2.083 (0.969–4.477)	0.0602	0.318 (0.137–0.736)	0.0074	2.864 (1.396–5.873)	0.0041	3.414 (1.649–7.069)	0.0009
Adjuvant radiotherapy								
No	1(ref)				1(ref)		1(ref)	
Yes	0.659 (0.249–1.744)	0.4006			2.655 (1.163–6.059)	0.0204	3.256 (1.428–7.423)	0.005

CCC clear cell carcinoma, NE neuroendocrine tumor, PLND pelvic lymph-node dissection, PALND para-aortic lymph node dissection

^a Adjusted model: adjusted age at diagnosis (≤ 50 vs > 50), FIGO stage

^b Multivariableb: adjusted age at diagnosis (≤ 50 vs > 50), FIGO stage

maintaining ovarian function, since adjuvant treatment can also induce menopause.

Endometrial cancer in premenopausal women has been shown to be hormone related, have early stage, no

myometrial invasion, and good prognosis [24]. If metastatic or synchronous malignancy has not been found in the ovary during surgery, ovarian preservation may be performed; therefore, surgical menopause of the patient

Table 3 Previous studies about ovarian preservation in endometrial cancer patients

Study	Year	Country	Period	Patients	Age	Stage	Grade	Histology	Follow up period (month)	Survival benefits
Wright	2009	USA	1988–2004	402/2867	45	Ia 64%, Ib 33%, Ic 3%	I 79%, II 14%, III 3%	endo	1–121	NS
Lee	2009	Korea	1993–2005	123/–	45	Ia 74%, Ib 23%, Ic 3%	I 70%, II 17%, III 2%	Endo (86%)	1–125	No recur, 5-yr OS:98%
Sun	2012	China	2002–2010	34/132	45	Ia 71%, Ib 22%, Ic 7%	I 70%, II 20%, III 10%	Endo (97%)	27–122	NS
Lee	2013	Korea	1997–2008	176/319		Ia 89% Ib 5% II 6%	I 78% II 18% III 4%	endo	6–208	NS
Wright	2016	USA	1998–2012	1121/14527	< 50	Ia 89% Ib 8% II 3%	I 60% II 27% III 6%	endo	61, median	NS
Wang	2016	China	2009–2015	25/76	< 45	Ia 87%, Ib 13%	I 75%, II 21%, III 40%	Endo (99%)		NS

NS non-specific

is not induced, which may be more beneficial to women's health. We recommend to consider the pathology of the tumor and the necessity of maintaining fertility before surgery.

Although this retrospective study has some limitations, this is the first study in which all patients had been diagnosed with endometrial cancer through preoperative endometrial biopsy, and had ovarian preservation or removal planned in advance of surgery, after confirming no other distant metastasis through computed tomography scan and lab test. Further, a relatively low ratio of patients was administered adjuvant treatment, so this study may serve as a reliable reference for early FIGO stage endometrial cancer. However, this study has limited data about the side effects of each group, especially menopausal problems that occur in the ovarian removal group. Long-term follow-up of adverse effects in postoperative patients may reveal significant differences in patients who have undergone surgical menopause. Second, although a small number of patients received adjuvant treatment after surgery, that treatment was related to survival; consequently, a more accurate group selection process is warranted for future studies.

Cancer survival and life expectancy after diagnosis are increasing, and quality of life issues are becoming more important. It is time for further prospective research to confirm whether it is more favorable to remove the ovaries to decrease risk of recurrence or to maintain patient quality of life through ovarian preservation.

Conclusions

Ovarian preserving surgery in early stage endometrial cancer is a beneficial option for premenopausal patients and is not related to disease recurrence or overall survival rate. More precise stratification analysis is needed to determine which additional groups may safely preserve the ovary.

Abbreviations

ASCO: American Society of Clinical Oncology; ESMO-ESGO-ESTRO: European Society for Medical Oncology, European Society of Gynaecological Oncology, and European Society for Radiotherapy & Oncology; FIGO: International Federation of Obstetrics and Gynecology; HRs: Hazard ratios; IRB: Institutional review board of our institution; NCCN: National Comprehensive Cancer Network; RFS: Recurrence free survival; OS: Overall survival

Acknowledgements

Not applicable.

Authors' contributions

Conceptualization: Wonkyo Shin, Sangsoo Seo. Data analysis: Wonkyo Shin. Manuscript draft: Wonkyo Shin. Manuscript revision and review: Myongcheol Lim, Sangyoon Park, Sokbom Kang. Supervision: Sangsoo Seo. The author(s) read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Ethics approval and consent to participate

This retrospective study was approved by the institutional review board of our institution (IRB No. NCC2019–0272).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Center for Gynecologic Cancer, Graduate School of Cancer Science and Policy, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 10408, Republic of Korea. ²Common Cancer Branch, Research Institute Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea. ³Precision Medicine Branch, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea. ⁴Department of Cancer Control & Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea. ⁵Center for Clinical Trials, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea. ⁶Cancer Healthcare Research Branch, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea.

Received: 1 May 2020 Accepted: 3 August 2020

Published online: 22 August 2020

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin.* 2017;67:7–30.
2. Lim MC, Won YJ, Ko MJ, Kim M, Shim SH, Suh DH, et al. Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999–2015. *J Gynecol Oncol.* 2019;30:e38.
3. Colombo N, Creutzberg N, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C, ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. *Ann Oncol.* 2016;27(1):16–41. <https://doi.org/10.1093/annonc/mdv484>.

4. Wright JD, Buck AM, Shah M, Burke WM, Schiff PB, Herzog TJ. Safety of ovarian preservation in premenopausal women with endometrial cancer. *J Clin Oncol*. 2009;27:1214–9.
5. Wright JD, Jorge S, Tergas AI, Hou JY, Burke WM, Huang Y, et al. Utilization and outcomes of ovarian conservation in premenopausal women with endometrial cancer. *Obstet Gynecol*. 2016;127:101–8.
6. Lee TS, Jung JY, Kim JW, Park NH, Song YS, Kang SB, et al. Feasibility of ovarian preservation in patients with early stage endometrial carcinoma. *Gynecol Oncol*. 2007;104:52–7.
7. Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. *JAMA Cardiol*. 2016;1:767–76.
8. Svejme O, Ahlborg HG, Nilsson JA, Karlsson MK. Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women. *BJOG*. 2012;119:810–6.
9. Bove R, Secor E, Chibnik LB, Barnes LL, Schneider JA, Bennett DA, et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. *Neurology*. 2014;82:222–9.
10. Doganay M, Kokanali D, Kokanali MK, Cavkaytar S, Aksakal OS. Comparison of female sexual function in women who underwent abdominal or vaginal hysterectomy with or without bilateral salpingo-oophorectomy. *J Gynecol Obstet Hum Reprod*. 2019;48:29–32.
11. Secosan C, Balint O, Pirtea L, Grigoras D, Balulescu L, Ilina R. Surgically induced menopause—a practical review of literature. *Medicina (Kaunas)*. 2019;55(8):482. <https://doi.org/10.3390/medicina55080482>.
12. Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. *Cochrane Database Syst Rev*. 2018;5:CD008830.
13. Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. *Fertil Steril*. 2016;106:1588–99.
14. Sun C, Chen G, Yang Z, Jiang J, Yang X, Li N, et al. Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis. *Fertil Steril*. 2013;100:782–7.
15. Lee TS, Kim JW, Kim TJ, Cho CH, Ryu SY, Ryu HS, et al. Ovarian preservation during the surgical treatment of early stage endometrial cancer: a nationwide study conducted by the Korean gynecologic oncology group. *Gynecol Oncol*. 2009;115:26–31.
16. Lee TS, Lee JY, Kim JW, Oh S, Seong SJ, Lee JM, et al. Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean gynecologic oncology group study. *Gynecol Oncol*. 2013;131:289–93.
17. Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. *J Natl Compr Cancer Netw*. 2018;16:170–99.
18. Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. *J Clin Oncol*. 2018;36:1994–2001.
19. Jia P, Zhang Y. Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer. *Oncotarget*. 2017;8:59940–9.
20. Rosendahl M, Andersen CY, la Cour FN, Juul A, Lossi K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. *Fertil Steril*. 2010;94:156–66.
21. Chemaitilly W, Li Z, Krasin MJ, Brooke RJ, Wilson CL, Green DM, et al. Premature ovarian insufficiency in childhood cancer survivors: a report from the St. Jude lifetime cohort. *J Clin Endocrinol Metab*. 2017;102(7):2242–50. <https://doi.org/10.1210/jc.2016-3723>.
22. Levine JM, Whitton JA, Ginsberg JP, Green DM, Leisenring WM, Stovall M, et al. Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: a report from the childhood cancer survivor study. *Cancer*. 2018;124:1044–52.
23. van Dorp W, Haupt R, Anderson RA, Mulder RL, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, et al. Reproductive function and outcomes in female survivors of childhood, adolescent, and young adult cancer: a review. *J Clin Oncol*. 2018;36:2169–80.
24. Carneiro MM, Lamaita RM, Ferreira MC, Silva-Filho AL. Fertility-preservation in endometrial cancer: is it safe? Review of the literature. *JBRA Assist Reprod*. 2016;20:232–9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

